An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 2, 1999, Pages 246-254

  Tashkin, Donald P ^a   Nathan, Robert A ^b   Howland, William C ^c   Minkwitz, Margaret C ^d   Simonson, Steven G ^d   Bonuccelli, Catherine M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Allergy Associates PC   (United States)

^c HealthQuest Therapy/Res Inst Inc   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Asthma; Leukotriene receptor antagonist; Leukotrienes; Pulmonary function; Subset analyses; Zafirlukast

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ZAFIRLUKAST;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERANCE; FEMALE; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; TOSYL COMPOUNDS;

EID: 0033011253     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70498-7     Document Type: Article

References (29)

1. Smith LJ. Leukotrienes in asthma: the potential therapeutic role of antileukotrienes. Arch Intern Med 1996;156:2181-9.
2. Spector SL. Leukotriene activity modulation in asthma. Drugs 1997;54:369-84.
3. Nathan RA. Anti-leukotriene agents: a new direction in asthma therapy. J Asthma 1996;33:353-66.
4. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996;98:1-13.
5. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
6. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther 1997;19:675-90.
7. Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate airflow obstruction. J Allergy Clin Immunol 1998;102:935-42.
8. Reiss TF, Chervinsky P, Dockhorn R, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998;158:1213-20.
9. Reiss TF, Sorkness CA, Stricker W, et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled cortico-steroid. Thorax 1997;52:45-8.
10. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-34.
11. Israel E, Cohn C, Dubé L, Drazen JM, Zileuton Clinical Trial Group. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996;275:931-6.
12. Liu MC, Dubé LM, Lancaster J, Zileuton Study Group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996;98:859-71.
13. National Asthma Education Prevention Program. Expert panel report II: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health; 1997. NIH Publication No 97-4501.
14. American Thoracic Society. 1994 Update: standardization of spirometry. Am J Respir Grit Care Med 1995;152:1107-36.
15. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials: a survey of three medical journals. N Engl J Med 1987;317:426-32.
16. US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Epidemiology and Biostatistics. COSTART: Coding symbols for thesaurus of adverse reaction terms. 5th ed. Rockville (MD); 1995. Publication no. PB95-595426 INC.
17. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (ACCOLATE™) or cromolyn sodium (INTAL™) in patients with mild to moderate asthma [abstract], J Allergy Clin Immunol 1995;95(suppl):388.
18. National Center for Health Statistics. Current estimates from the National Health Interview Survey, 1994. Series 10 (No. 193). Hyattsville (MD); 1995. DHHS publication no. 96-1521.
19. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116:78-84.
20. Fleming TR. Interpretation of subgroup analyses in clinical trials. Drug Inf J 1995;29:1681S-7S.
21. Ray NF, Thamer M, Fadillioglu B, Gergen PJ. Race, income, urbanicity, and asthma hospitalization in California: a small area analysis. Chest 1998;113:1277-84.
22. Beckett WS, Belanger K, Gent JF, Holford TR, Leaderer BP. Asthma among Puerto Rican Hispanics: a multi-ethnic comparison study of risk factors. Am J Respir Crit Care Med 1996;154:894-9.
23. Nelson DA, Johnson CC, Divine GW, Strauchman C, Joseph CLM, Ownby DR. Ethnic differences in the prevalence of asthma in middle class children. Ann Allergy Asthma Immunol 1997;78:21-6.
24. Higgins BG, Britton JR, Chinn S, et al. The distribution of peak expiratory flow variability in a population sample. Am Rev Respir Dis 1089;140:1368-72.
25. Quackenboss JJ, Lebowitz MD, Krzyzanowski M. The normal range of diurnal changes in peak expiratory flow rates: relationship to symptoms and respiratory disease. Am Rev Respir Dis 1991;143:323-30.
26. Enright PL, Burchette RJ, Peters JA, Lebowitz MD, McDonnell WF, Abbey DE. Peak flow lability: association with asthma and spirometry in an older cohort. Chest 1997;112:895-901.
27. Spector S, Miller CJ, Glass M. 13-Week dose response study with ACCOLATE™ (zafirlukast) in patients with mild to moderate asthma [abstract]. Am J Respir Crit Care Med 1995;151(suppl):A379.
28. nd Ed. Zafirlukast prescribing information. Montvale, NJ: Medical Economics Company, 1998:3148-9.
29. 4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy. Ann Allergy Asthma Immunol 1998;81:43-9.